Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.
A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide. Laboratory studies yielded substantially increased serum procollagen III levels and anticardiolipin antibodies accompanied with anti-beta(2) glycoprotein I, findings not previously described with this disorder. Clinical and laboratory manifestations resolved after cessation of methysergide therapy.
Bucci
J A
JA
Department of Clinical Haematology, St. George Hospital, Sydney, NSW, Australia.
Manoharan
A
A
D000328:Adult; D005260:Female; D006801:Humans; D008784:Methysergide / Q000009:adverse effects*; D008881:Migraine Disorders / Q000188:drug therapy; D012185:Retroperitoneal Fibrosis / Q000097:blood / Q000139:chemically induced*; D014662:Vasoconstrictor Agents / Q000009:adverse effects*
D014662:Vasoconstrictor Agents; D008784:Methysergide